| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
NOTTINGHAM, U.K.—Looking to expand its enzyme operations, Novozymes acquired Delta Biotechnology from the sanofi-aventis group. The new company, Novozymes Delta, will continue to operate as a self-contained business unit, developing and manufacturing recombinant proteins using engineered proprietary yeast strains.
 
"Novozymes will set the direction and has the resources that will enable us to further progress our yeast-based protein expression capabilities to the benefit of our global customer base," said Dermot Pearson, commercial operations director of Novozymes Delta. "The market for safe, animal-free recombinant proteins is growing and, with Novozymes backing us, we'll be in a great position to satisfy this market".
 
Novozymes Delta will also license its technology to pharmaceutical, healthcare and biotechnology partner companies as customized solutions, offering it a strong position in the industrial enzymes market. According to a July 2005 report by Freedonia Group, this market hit $3.7 billion and was expected to grow at 6.5 percent a year to 2009.
 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Three burgundy round and linear conformations of oligonucleotides are shown against a black background.

Accelerating RNA therapeutic testing with liver microphysiological platforms

Researchers can now study oligonucleotide delivery and efficacy in a system that models a real human liver.
A 3D-rendered illustration of a eukaryotic cell highlighting organelles such as the nucleus, endoplasmic reticulum, mitochondria, and cytoskeletal structures in pink and purple tones.

Shining light on the subcellular proteome

Discover how innovative proteomics tools help researchers peer into once inaccessible organelles, allowing for new targets for drug discovery and development.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue